Participated · Series B · Aug 2026

Vaderis is developing engasertib (VAD044), an investigational once-daily oral selective allosteric AKT1/2 inhibitor intended to treat hereditary hemorrhagic telangiectasia (HHT). The company has advanced engasertib into pivotal development following positive proof-of-concept and long-term extension data published in The New England Journal of Medicine. Vaderis has initiated HEROIC, a global Phase 3 randomized, double-blind, placebo-controlled study enrolling patients across North America, South America and Europe. The company intends to use proceeds from its $152 million Series B to support operations through regulatory submissions and potential U.S. approval. Vaderis is headquartered in Basel, Switzerland, with a U.S. subsidiary in Lincolnshire, Illinois. The company positions engasertib as a potential first approved therapy specifically developed for people living with HHT.

Participated · Equity · May 2026

Mentari’s lead programs are MT-001, an anti-PACAP monoclonal antibody slated for first-in-human regulatory filings in mid-2026, and MT-002, an anti-CGRP x PACAP bispecific antibody expected to enter regulatory filings in the first quarter of 2027. The programs were discovered by Paragon Therapeutics and have shown strong in vitro potency and favorable pharmacokinetic profiles in preclinical studies. The therapies are designed to target complementary migraine pathways and address patients who experience limited benefit from currently approved anti-CGRP treatments. Mentari announced a $290 million private placement that it says will fund operations through 2028 and entered an all-stock merger agreement with InMed Pharmaceuticals to gain public market infrastructure. Following the transaction the combined company is expected to trade on the Nasdaq Capital Market and have a pro forma equity value of approximately $421.4 million, with pre-merger InMed shareholders holding about 1.51% of the combined company. The company and merger parties expect to accelerate development timelines and pursue regulatory filings according to the stated milestones.

Led · Convertible Note · Mar 2026

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Participated · Equity · Mar 2026

MedinCell, headquartered in Jacou near Montpellier, specializes in proprietary long-acting injectable drug formulations designed to improve patient adherence across several therapeutic areas. Its portfolio already includes a schizophrenia treatment that Teva commercializes in the United States. The company employs roughly 140 people and generated €27.7 million in revenue in fiscal-year 2024. With the new capital, MedinCell plans to accelerate value-adding partnerships to launch additional programs and to upgrade its technology platform with next-generation injection technologies. Management intends to leverage these innovations to broaden the pipeline and reinforce the firm’s leadership in sustained-release injectables. The strategy focuses on both internal R&D and external collaborations to expand clinical and commercial reach.

Led · Series D · Feb 2026

Talkiatry operates a nationwide, in-network psychiatric care service that partners with health systems, payers, and employers to offer dependable access to mental-health treatment. The company directly employs more than 800 full-time psychiatrists, making it the largest private employer of psychiatrists in the United States. To date, Talkiatry has facilitated 3 million patient visits. Its proprietary AI-powered technology streamlines clinical workflows, manages care delivery, and increases member engagement. The firm generates revenue by contracting in-network with insurers and other partners while leveraging its scale to improve utilization and outcomes. With fresh capital in hand, Talkiatry plans to deepen investment in its technology stack and broaden its services across the acuity spectrum. Cumulatively, the company has now raised over $400 million to finance its growth and platform development.